The groundbreaking clinical trial of GDNF, a potential treatment for Parkinson's, is now complete. Analysis of the results is now well underway and is expected to be published in the coming months.
New research published in Nature Biotechnology shows that it may be possible to reprogramme cells inside the brain to reverse the symptoms of Parkinson's.
Parkinson's UK and the University of Sheffield have launched a new £1million virtual biotech company, Keapstone Therapeutics, to combine world-leading research from the University with funding and expertise from the charity to develop new treatments.
Researchers have discovered a potential way to tell the difference between people with Parkinson's and those with parkinsonisms using a simple blood test.